Inhibition of Ephrin B2 Reverse Signaling Suppresses Multiple Myeloma Pathogenesis

By sjmartinez • January 18, 2024

Sasine JP, Kozlova NY, Valicente L, Dukov J, Tran DH, Himburg HA, Kumar S, Khorsandi S, Chan A, Grohe S, Li M, Kan J, Sehl ME, Schiller GJ, Reinhardt B, Singh BK, Ho R, Yue P, Pasquale EB, Chute JP. Inhibition of Ephrin B2 Reverse Signaling Suppresses Multiple Myeloma Pathogenesis. Cancer Res. 2024 Jan 17. doi: 10.1158/0008-5472.CAN-23-1950. Epub ahead of print. PMID: 38231476.

Tags: Hematology/Oncology, Publications

OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML

Borate UM, Huang Y, Lin TL, Handa S, Swords R, Lachowiez CA, Traer E, Stock W, Odenike O, Patel AA, Baer MR, Duong VH, Stein[...]

Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004

Wierda WG, Dorritie KA, Gauthier J, Nath R, Kipps TJ, Riedell PA, Eradat HA, Kenderian SS, Kharfan-Dabaja MA, Shah NN, Solomon SR, Stephens DM, Ermann[...]

Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis